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1. Introduction 
Oxidative stress is thought to contribute to the development of a wide range of diseases 
including neurodegenerative (Alzheimer, Parkinson, Amyotrophic Lateral Sclerosis…), 
diabetes, cancer, rheumatoid arthritis, cardiovascular and liver diseases several of them are 
related with low levels of IGFs such as degenerative and aging disorders [1-8].  
Oxidative stress represents an imbalance between the production of ROS/RNS and a 
biological system's ability to detoxify the reactive intermediates or to repair the resulting 
damage. In normal conditions ROS are reduced into water. For these reason cells are 
protected against oxidative stress by an interacting network of antioxidant enzymes. This 
detoxification pathway is the result of several enzymes, with Superoxide Dismutase (SOD, 
EC 1.15.1.1) catalyzing the first step O2 into H2O2 and Catalase (CAT; EC. 1.11.1.6) and 
Glutathione Peroxidase (GSH-Px; EC 1.11.1.9) removing H2O2 into H2O by two different 
pathways. Disturbances in the normal redox state of tissues can cause toxic effects through 
the production of peroxides and free radicals exert deleterious effects on cell through direct 
attack on DNA, proteins or membrane lipids (including mitochondrial lipids). These 
oxidative damages lead to the cellular death. The mechanisms of oxidative cellular damage 
are summarized in Fig. 1. 
The main sources of ROS/RNS are: exogenous ( irradiation, UV irradiation, drugs, 
xenobiotics, and toxin metabolism) and endogenous (metabolic pathways, mitochondrial 
respiration, oxidative burst, fagocytosis, enzyme activities, aging and diseases).  
Although the exposure of the organism to ROS/RNS is extremely high from exogenous 
sources, the exposure to endogenous sources is much more important and extensive, 
because it is a continuous process during the life span of every cell in the organism. 




Figure 1. Mechanisms of oxidative cellular damage. Free radicals are reduced into water with the 
cooperation of the three main antioxidant enzymes: SOD, Catalase, and GSHPx. The generation of 
hydroxyl radicals from hydroperoxide produces the development of oxidative cell injury: DNA 
damage; carboxylation of proteins; and lipid peroxidation, including lipids of mitochondrial 
membranes. By these pathways, oxidative damage leads to cellular death. [5] 
Mitochondria are the major endogenous source of ROS underphysiologycal conditions, 
because 2% to 3% of the O2 consumed is converted to O2-. Intramitochondrial ROS 
production increases after peroxidation of intramitochondrial membrane lipids. 
Furthermore mitochondria are particularly sensitive to ROS/RNS-induced injury in the 
pathogenesis of disease. Oxidative stress exerts deleterious effects on mitochondria function 
by directly impairing oxidative phosphorylation through direct attack of proteins or 
membrane lipids. ROS/RNS can also induce mitochondrial DNA deletions and 
mitochondrial membrane permeability transition (MMPT). MMP pore opening activates 
caspases, which is an endpoint to initiate cell death. Recently, a large number of studies 
have associated mitochondrial dysfunction caused by ROS/RNS to both accidental cell death 
(necrosis) and programmed cell death (apoptosis).  
Continuous exposure to various types of oxidative stress from numerous sources has led the 
cell and the entire organism to develop defense mechanisms for protection against reactive 
metabolites. Mitochondrial like a source of ROS are summarized in Fig. 2.  
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Figure 2. Mitochondrial damage is an intracellular source of ROS. Oxidative stress exerts deleterious effects 
on mitochondria function by directly impairing oxidative phosphorylation through direct attack of 
proteins or membrane lipids. Mitochondrial damage produces mitochondrial dysfunction decreasing 
MMP and ATP synthesis and increasing ROS production. 
Understanding that mitochondria are the most important cellular targets of IGF-I [5, 6, 7] 
and it is the main intracellular source of ROS our results show a novel mechanism for 
oxidative stress regulation through mitochondrial protection and normalization of 
antioxidants enzymes activities by IGFs signaling pathways. 
2. Oxidative Stress: Mitochondrial damage and antioxidant denfences 
2.1. Mitochondrial damage 
Mitochondria play a central role in many cellular functions including energy production, 
respiration, heme synthesis, and lipids synthesis, metabolism of amino acids, nucleotides, 
and iron, and maintenance of intracellular homeostasis of inorganic ions, cell motility, cell 
proliferation and apoptosis [8, 9]. Mitochondria contain their own DNA (mtDNA). The 
mtDNA occurs in small clusters called nucleoids or chondriolites. The number of mtDNA 
molecules in nucleoids varies in size and numbers in response to physiological conditions. 
While nuclear DNA encodes the majority of the mitochondrial proteins only a few of these 
proteins are encoded by mitochondrial DNA. A recent mitochondrial proteomic study in S. 
cerevisiae identified at least 750 mitochondrial proteins that perform mitochondrial function 
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[10]. The last decade has witnessed an increased interest in mitochondria, not only because 
mitochondria were recognized to play a central role in apoptosis but also since 
mitochondrial genetic defects were found to be involved in the pathogenesis of a number of 
human diseases [9,11]. 
A variety of cellular systems, including NADPH oxidase, xanthine oxidase, uncoupled 
eNOS (endothelial NO synthase) and cytochrome P450 enzymes, can generate ROS, but, in 
most mammalian cells, mitochondria are the principal organelles for ROS production. The 
production of mitochondrial ROS is a consequence of oxidative phosphorylation at the 
respiratory chain complexes I and III where electrons derived from NADH and FADH can 
directly react with oxygen or other electron acceptors and generate free radicals [12-14]. 
Indeed, the increase of the redox potential at complex I and complex III induces ROS 
generation [15, 16]. Mitochondria are also a major site for the accumulation of low molecular 
weight Fe2+ complexes, which promote the oxidative damage of membrane lipids [17-19]. 
Mitochondria do not only represent the major source of ROS production but they are also 
the major targets for their damaging effects. Mitochondrial DNA (mtDNA) seems to be 
highly vulnerable to oxidative challenges compared to nuclear DNA for three main reason: 
1) its close proximity to the electron transport chain (ETC), 2) it is continuously exposed to 
ROS generated during oxidative phosphorylation (it is estimated that up to 4% of the 
oxygen consumed by cells is converted to ROS under physiological conditions) [20] and 3) 
its limited capacity of DNA repair strategies and the lack of protection by histones [21]. ROS 
also produce more than 20 types of mutagenic base modifications in DNA [22]. These DNA 
lesions cause mutations in mtDNA that can lead to impairment of mitochondrial function 
[23]. Taken together, this makes clear that mtDNA is extremely susceptible to mutation by 
ROS-induced damage. Given that mitochondria are the major producer of ATP, it is also 
likely that mitochondrial dysfunction leads to the reduction in ATP level that may affect 
ATP-dependent pathways involved in transcription, DNA replication, DNA repair, and 
DNA recombination. Mitochondria are intimately involved in deoxyribose nucleoside 
triphosphate (dNTP) biosynthesis [24]. It is conceivable that mitochondrial damage 
contributes to muta-genesis of the nuclear genome in part due to impaired nucleotide 
biosynthesis. In fact, it is well established that an imbalance in the dNTP pool is mutagenic 
to cells [25]. Studies demonstrate that a dNTP pool imbalance can induce nucleotide 
insertion, frame-shift mutation [25] sister chromatid exchange, recombination and double-
strand break [26]. 
Mitochondria also play a key role in regulation of apoptosis under a variety of pathological 
conditions, including ischemia, hypoxia, and myocardial infarction [27-30]. The 
electrochemical potential across mitochondrial membrane, MMP, is known to be highly 
sensitive to apoptotic stimulation. As an index of mitochondrial function in living cells, 
MMP can be measured with an indicator dye, e.g., rhodamine 123 (Rh123), which fluoresces 
in direct proportion to MMP [31]. Decreased MMP occurs in cells undergoing apoptosis 
induced by oxidative agents, such as H2O2 in primary neuronal cultures [32]. Injured 
mitochondria can release cytochrome-c into the cytoplasm when cells are treated with 
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proapoptotic stimuli [33]. Cytochrome-c activates the apoptosome containing the caspase-
activating protein Apaf-1 and subsequently the caspase cascade that induce apoptosis [34].  
Because macromolecules in mitochondria (including mtDNA) are particulary susceptible to 
oxidative damage of mitochondrial turnover is critical for the maintenance of a healthy 
mitochondrial phenotype, normal energy production, and the promotion of healthy aging 
[35]. Mitochondria are highly dynamic organelles, and deregulation of mitochondrial 
turnover is likely one of the intrinsic causes of mitochondrial dysfunction, which contributes 
to deregulation of cell metabolism, oxidative stress, and altered signal transduction during 
the aging process. 
Autophagy is a catabolic process that contributes to the maintenance of cellular homeostasis 
through the degradation of damaged mitochondria in lysosomes. The available evidence 
suggests that there is an age-dependent decline in autophagic function, which likely 
contributes to the accumulation of damaged non-functional mitochondria. In addition, 
dysfunction of the proteasomes [36] may be also contributed to the accumulation of 
damaged mitochondrial proteins in the age diseases.  
Mitochondria are important cellular targets of IGF-I [5, 6], different groups have described that 
IGF-I decreases mitochondrial superoxide production [37] and low levels of IGF-I have been 
linked to increase in oxidative stress damage [3, 5, 40-42]. IGF-I also acts as an anti-apoptosis 
factor of multiple cell types, and its anti-apoptotic effects occur through engagement with IGF-
I receptor (IGF-IR) and thought to activate an intracellular signal transduction pathway that 
may modulate the mitochondria, cytochrome c and caspase pathway [38, 39]. Recent studies 
show that treatment of aged rodents with IGF-I confer mitochondrial protection, including an 
attenuation of mitochondrial ROS generation in the liver [40-42]. The available data suggest 
that treatments that increase circulating IGF-I levels exert citoprotective effects in aging and 
degenerative diseases [1-3, 5-7, 42]. Thus, further studies are necessary to determine the role of 
mitochondrial mechanisms in beneficial effects of IGF-I treatment, including the effects of IGF-
I on autophagy of dysfunctional mitochondria and apoptosis. 
2.2. Antioxidant defenses 
ROS and RNS consist of radicals and other reactive oxygen/nitrogen factors that can react 
with other substrates. Examples of ROS and RNS are superoxide, nitric oxide, peroxynitrite 
and hydrogen peroxide. Under physiological conditions, these are counterbalanced by an 
array of defense pathways, and it needs to be emphasized that ROS and RNS have many 
physiological roles that include signaling. In excess, or in situations where defenses are 
compromised, ROS and RNS may react with fatty acids, proteins and DNA, thereby causing 
damage to these substrates. Under normal conditions, antioxidant defenses include the 
enzymatic and non-enzymatic defense systems regulate the ROS and RNS produced. 
Antioxidants regulate oxidative and nitrosative reactions in the body and may remove ROS 
and RNS through scavenging radicals, decreasing the production of ROS and RNS, thus 
preventing the damage caused by ROS and RNS.  
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a. Enzymatic defense systems. 
Enzymatic defense systems such as Superoxide Dismutases (SOD), Catalases (CAT), 
Glutathione Peroxidases (GPx), Glutation Reductases (GSR or GR; EC 1.8.1.7) and Glutathione 
Transferases (GST; EC 2.5.1.18) protect mitochondria and DNA from oxidative stress. It has 
been proposed that polymorphisms in these enzymes are associated with DNA damage and 
subsequently the individual’s risk of wide range of diseases susceptibility [42, 43]. 
Superoxide Dismutases catalyze the dismutation of O2- to H2O2 and O2, rendering the 
potentially harmful superoxide anion less hazardous. SODs require a metal cofactor for 
function and can be grouped by the bound metal ion [44-46]. Iron containing SODs have 
been found in prokaryotes and some plants. Manganese SODs (MnSOD) are found in both 
prokaryotes and eukaryotes and are localized primarily to the mitochondria. MnSOD is 
encoded by the SOD2 gene mapping to chromosome 6 in human. The third class represents 
SODs, which require both copper and zinc as cofactors (Cu-Zn SODs). Cu-Zn SODs are 
homodimers in eukaryotes and are located predominantly in the cytoplasm. In most 
prokaryotes, Cu-Zn SODs exist as homodimers found in the periplasm. Human Cu-Zn SOD, 
encoded by the SOD1 gene mapping to chromosome 21, has been implicated as the source 
of some cases of familial Amyotrophic Lateral Sclerosis (ALS) [47, 48]. The eukaryotic 
extracellular SOD is a subset of the Cu-Zn variety but functions as a tetramer rather than the 
usual dimmer found in eukaryotes. Human extracellular Cu-Zn SOD, encoded by the SOD3 
gene mapping to chromosome 4 [49], SOD3 protein can be measured in plasma, lymph, 
cerebrospinal, and synovial fluids [50, 51]. Almost all human tissues contain measurable 
levels of SOD3 and at least eight different tissues; including heart, lungs, and placenta, 
synthesize SOD3 mRNA. SOD3 is the primary enzymatic antioxidant defense of the 
vascular wall. The physiopathological role of SOD 3 has been examined in vascular-related 
diseases, atherosclerosis, hypertension, diabetes, ischemia-reperfusion injury, lung disease, 
various inflammatory conditions, and neurological diseases. 
Catalase catalyzes the reduction of H2O2 to water using either an iron or manganese cofactor 
[52, 53]. CAT is a common antioxidant enzymes found in nearly all-living organisms that are 
exposed to oxygen and they can also remove organic H2O2 to oxidize toxins including 
phenols, formic acid, and hydroperoxides. CAT is present only or primarily in the 
peroxisome fraction and is absent in mitochondria of mammalian cells, except rat heart 
mitochondria [54]. Therefore, the only enzymatic defense system against hydrogen peroxide 
in mitochondria is the glutathione redox cycle system.  
CAT is a homotetramer encoded by ctt1 gene mapping in chromosome 11 [55]. 
Genetic polymorphisms in catalase and its altered expression and activity are associated 
with oxidative DNA damage and subsequently the individual’s risk of cancer susceptibility 
[56]. A few polymorphisms have been described for the catalase-encoding gene; these are 
normally related with the development of mental disorders [57]. Humans with low catalase 
levels (acatalasemia) have an increased risk for diabetes mellitus; while the clinical features 
of acatalasemia are oral gangrene, altered lipid, carbohydrate, homocysteine metabolism 
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and the increased risk of diabetes mellitus [58] and lower levels of catalase activity in other 
tissues, seem to be asymptomatic. 
Glutathione Peroxidase (GPx) are critical intracellular enzymes involved in the reduction of 
hydrogen peroxide H2O2 to water and lipid peroxides to their corresponding alcohols using 
selenium cofactor in the majority of the cases. GPx are present both in the cytosol and in 
mitochondria [59]. There are at least eight GPx enzymes: GPx1–GPx8 [60, 61]. The GPx 1-8 
genes mapping to chromosomes 3, 14, 5, 19, 6, 6, 1 and 5 respectively. Whereas GPx1 is the 
most abundant selenoperoxidase and is ubiquitously expressed in almost all tissues [60, 61], 
GPx2 expression is most prominent in the gastrointestinal tract [62]. Expression of GPx3 is 
greatest in the kidney, although this enzyme is expressed in various tissues and is secreted 
into extracellular fluids as a glycoprotein [63, 64]. Different from other glutathione 
peroxidases, GPx4, or phospholipid hydroperoxide GPx, is not a tetramer, but rather a 
monomer, and is the only GPx enzyme that reduces phospholipid hydroperoxides [65]. In 
addition, GPx4 contains a mitochondrial isoform that mediates the apoptotic response to 
oxidative stress [66, 67] and has a peroxidase independent structural role after sperm 
maturation [68]. GPx6 was identified as a selenoprotein in the human genome by homology 
search [69]. However, GPx6 from rodents and GPx5 from both humans and rodents do not 
contain Sec or Se [69]. Recently, GPx7 and GPx8 were also identified as selenium-
independent GPx can act as true H2O2 scavengers, as expected of the selenium-dependent 
members [70-73]. Lower GPx activity predispose towards an impaired antioxidant 
protection and consequently stress oxidative damage to membrane fatty acids and 
functional proteins and, by inference, to neurotoxic damage, and hence the process of 
neuroprogression that accompanies severe or persistent illness [74]. 
Glutathione Reductase, also known as GSR or GR, is an enzyme that reduces glutathione 
disulfide (GSSG) to the sulfhydryl form GSH, which is an important cellular antioxidant [75, 
76]. GSR is a homodimer found are present both in the cytosol and in mitochondria. 
For every mole of oxidized glutathione (GSSG), one mole of NADPH is required to reduce 
GSSG to GSH. The enzyme forms a FAD-bound homodimer. Human GSR gene mapping to 
chromosome 8. The GR is conserved between all kingdoms. In bacteria, yeasts, and animals, 
one gr gene is found; however, in plant genomes, two gr genes are encoded. Drosophila and 
Trypanosomes do not have any GR at all [76]. In these organisms, glutathione reduction is 
performed by either the thioredoxin or the trypanothione system, respectively [77, 78]. In 
cells exposed to high levels of oxidative stress, like red blood cells, up to 10% of the glucose 
consumption may be directed to the pentose phosphate pathway (PPP) for production of the 
NADPH needed for this reaction. In the case of erythrocytes, if the PPP is non-functional, 
then the oxidative stress in the cell will lead to cell lysis and anemia [79].  
Glutathione Transferases have also been called glutathione S-transferases, GST. These 
enzymes catalyze nucleophilic attack by reduced glutathione (GSH) on nonpolar 
compounds that contain an electrophilic carbon, nitrogen, or sulphur atom. Their substrates 
include halogenonitrobenzenes, arene oxides, quinones, and α,β-unsaturated carbonyls [80-
84]. Three major families of proteins that are widely distributed in nature exhibit glutathione 
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transferase activity. Two of these, the cytosolic and mitochondrial GST, comprise soluble 
enzymes that are only distantly related [85, 86]. The third family comprises microsomal GST 
and is now referred to as membrane-associated proteins in eicosanoid and glutathione 
(MAPEG) metabolism [87].  
Cytosolic GSTs of mammals have been particularly well characterized, and were originally 
classified into Alpha, Mu, Pi, Theta, Zeta and Omega classes on the basis of a 
substrate/inhibitor specificity, primary and tertiary structure similarities and immunological 
identity [88]. The alpha class genes (GSTA1-5), located in a cluster mapped to chromosome 
6, play an important role in cellular protection against oxidative stress and they are the most 
abundantly expressed glutathione S-transferases in liver. Decreased in alpha class GSTs has 
been observed in stomach and liver tumors. A significant decrease of glutathione transferase 
activity was described in amygdala, hippocampus and inferior parietal lobule in patients 
with AD [89]. The Mu class of GSTs has five genes (GSTM1–5) [90] that are found in a gene 
cluster on chromosome 1 [91]. The GSTM1 gene contains four alleles that have been 
associated with a decreased risk of bladder cancer [92]. Neurodegenerative diseases such as 
PD and schizophrenia are characterized by the degeneration of dopaminergic neurons. 
GSTM2-2 has been shown to catalyze the conjugation of GSH to aminochrome, a ROS 
generated in the redox cycling of orthoquinones within dopaminergic neurons [93]. Hence, 
GSTM2-2 has been proposed to play a protective role against neurodegenerative diseases. 
The Theta class of GST has a null phenotype whereby individuals do not express 
catalytically active protein. The lack of enzyme activity, and therefore, an inability to 
detoxify carcinogens is associated with an increased risk toward a variety of cancers. The 
null phenotype is associated with an increased risk of tumors of the head and neck, oral 
cavity, pharynx, and larynx [94, 95]. The chromosomal locations of the genes that encoded 
for the different types of GST and the related diseases are summarized in table 1. 
b. Non-enzymatic defense systems. 
Examples of non-enzymatic defense systems are scavenger antioxidants (coenzyme Q10, 
vitamin C and E, and glutathione) and some proteins which act as antioxidants by binding 
ROS and RNS, e.g. thioredoxin (Trx), SS-peptides and acute phase proteins such as albumin, 
transferrin, haptoglobin and ceruloplasmin. These antioxidant systems thus protect the 
tissues against ROS and RNS. 
Coenzyme Q10 (CoQ10) is an endogenous compound found in the inner mitochondrial 
membrane, is essential to electron transport and ATP production via the respiratory 
chain. CoQ10 is a strong anti-oxidant that confers resistance to mitochondrial damage by 
decreasing ROS/RNS production and that may suppress the production of 
proinflammatory substances, like nuclear factor κ B (NFκB) gene expression and the 
production of pro-inflammatory cytokines [95-100]. CoQ10 and vitamin E are lipophylic 
antioxidants that are target to mitochondrial matrix by Tripenylphoshonium ion (TPP+) 
(mitoQ and mitovitamin E). These mitochondrial-targeted drugs can achieved 
concentrations in the mitochondrial matrix 100- to 1000-fold higher than those in the 
cytosol because of their strong positive charge, as mitochondria have a highly negative  
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Table 1. Enzymatic defense systems 
membrane potential between -150 mV and -180 mV. Both clinical and rodent studies have 
reported moderately beneficial actions of CoQ10 in reducing blood pressure, decreasing 
blood glucose, forestalling myocardial damage secondary to chemotherapeutic 
administration, limiting tumor growth, enhancing endothelial function and improving 
cognitive function in both Alzheimer’s and Parkinson’s disease patients [101]. However, one 
of the major limiting factors in the use of CoQ10 as a supplement is its bioavailability and 
delivery to the source of ROS generation. 
Several other studies have used MitoQ10 in a variety of animal models of disease [102] and 
the results indicate that MitoQ10 protects against liver damage in an animal model of sepsis 
[103], contributes to the aetiology of the metabolic syndrome and atherosclerosis in a mouse 
model [104] protects pancreatic β-cells against oxidative stress and improves insulin 
secretion in glucotoxicity and glucolipotoxicity [105] and even protects against oxidative 
stress and cell death in the brain of rats exposed to the insecticide dichlorvos [106]. 
Importantly, the first clinical evidence of a potential benefit of MitoQ10 in humans comes 
from a study that MitoQ10 reduces liver damage induced by hepatitis virus infection [107]. 
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Glutathione is formed in the liver from three amino acids, namely glycine, glutamine and 
cysteine. Cysteine is the rate-limiting step in the synthesis of reduced glutathione (GSH), the 
active form of glutathione. Glutathione has three major functions: 1) it is a strong 
antioxidant that protects cells against damage caused by free radicals and it recycles vitamin 
C and E, so that they again become active as antioxidants after been used in antioxidant 
processes. b) Glutathione is employed by the white blood cells as a source of energy used for 
lymphoproliferation. Therefore, glutathione may help increase the resistance to bacterial 
and viral infections. c) Glutathione is a natural purifier and therefore high concentrations 
are found in the liver. 
SS-Peptides the Szeto-Schiller (SS) compounds are tetrapeptides with an alternating aromatic-
cationic amino acids motif, and demonstrated in the inner mitochondrial membrane more than 
1000-fold in comparison with the cytosolic concentration [108-110]. Although the positive 
charge might explain the mitochondrial-targing effect, the mitochondrial uptake of these SS 
peptides appears to be on mitochondrial potencial, as they are concentrated even in 
depolarized mitochondria [91, 92]. SS peptides are capable of scavenging H2O2 and ONOO− 
and inhibiting lipid peroxidation. By reducing mitochondrial ROS production, these molecules 
inhibit MMPT and cytochrome c release and so prevent oxidant-induced cell death [111]. 
Using these peptides in an animal model of ischaemia/reperfusion injury improves cardiac 
function [112]. Whereas treatment with SS peptides attenuated mitochondrial H2O2 release 
induced by a high-fat diet and preserved insulin sensitivity in skeletal muscle [113]. 
Importantly, pre-clinical studies support the use of these peptides during 
ischaemia/reperfusion injury and neurodegenerative disorders [114]. 
Thioredoxin (Trx) is a multifunctional low-molecular weight protein containing an active 
thiol/disulphide site and possessing oxido reductase activity. Originally discovered in E. coli, 
Trx was later found in many prokaryotic and eukaryotic cells. The major Trx isoforms are 
cytosolic Trx1 and mitochondrial Trx2. Thioredoxins evolved similarly to chaperone-like 
proteins, whose function is maintenance of the dithiol/disulphide structure of proteins. A highly 
conservative amino acid sequence of the active centre (Trp-Cys-Gly-Pro-Cys- Lys) contains two 
active Cys residues (Cys32 and Cys35 in human Trx1 and Cys90 and Cys93 in human Trx2) that 
are oxidized into corresponding disulphides due to the transfer of two reducing equivalents 
from Trx to a disulphide-containing substrate. The disulphides formed in the active centres of 
Trx1 and Trx2 are reduced by thioredoxin reductase (TrxR). TrxR is an NADPH-dependent 
homodimer of oxidoreductase which reduces the active centre of disulphide in oxidized Trx 
and has two major isoforms, cytosolic (TrxR1) and mitochondrial (TrxR2). The Trx system plays 
a key role in cell function by limiting oxidative stress directly via antioxidant effects and 
indirectly by protein – protein interactions [115]. Cellular redox regulation of many processes is 
provided by the cooperation between the Trx and glutathione systems [115, 116]. Trx and GSH 
systems are involved in a variety of redox-dependent pathways such as supplying reducing 
equivalents for ribonucleotide reductase and peptide methionine sulphoxide reductase, the 
latter being involved in antioxidant defense and regulation of the cellular redox state [117]. The 
promoter of the Trx gene contains a series of stress responsive elements, various transcription 
factor binding sites, such as SP1, AP-1, NFkB and antioxidants response elements (ARE) [118]. 
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c. Antioxidant defense systems against mitochondrial ROS formation. 
The mitochondrial respiratory chain, located in the inner mitochondrial membrane (IM), is 
composed of four multimeric integral membrane proteins complexes (complexes I-IV), 
coencymeQ (CoQ), and cytochrome c (cyt c). Complex I accepts electrons from NADH and 
complex II accepts electrons from succinate. Electrons then move down an electrochemical 
gradient through CoQ to complex III, from complex III to cyt c, and from cyt c to complex IV, 
which uses four electrons to reduce molecular oxygen to water (Fig. 3). The production of 
mitochondrial ROS is a consequence of oxidative phosphorylation at the respiratory chain 
complexes I and III where electrons derived from NADH can directly react with oxygen or 
other electron acceptors and generate free radicals [12-14]. Indeed, the increase of the redox 
potential at complex I and complex III induces ROS generation [15, 16]. Mitochondrial and cell 
cytosolic antioxidant systems can neutralize excess mitochondrial ROS under most conditions. 
With the exception of generation at complex III, ROS production in mitochondria is exclusively 
directed towards the matrix where MnSOD catalyses dismutation to H2O2 [119] which is then 
reduced to H2O by GSH and Trx systems (Trx2) [120]. As the regeneration of GSH and reduced 
Trx2 depends on the NADPH/NADP+ redox state, an efficient mitochondrial bioenergetic 
function is required to maintain antioxidant activity. Matrix ROS can also pass through the 
MMTP, formed by voltage-dependent anion channel (VDAC), cyclophilin D (cyp D) and the 
adenine nucleotide translocator (ANT), directly to the cytosol where Cu-Zn SOD catalyses 
dismutation to H2O2 [119] which is then reduced to H2O by catalase. Complex III generates ROS 
on both sides of the mitochondrial inner membrane and in the intermembrane space, where Cu-
Zn SOD converts O2− into H2O2, which diffuses in the cytosol where catalase reduces it into 
H2O. Thus the efflux of H2O2 from the mitochondria is relatively modest, but may be modulated 
by either mitochondrial ROS themselves or changes in antioxidant defenses. 
 
Figure 3. Antioxidant defense systems against mitochondrial ROS formation 
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d. Regulation of enzymatic antioxidant defense systems. 
In order to prevent oxidative stress, the cell must respond to ROS by mounting an 
antioxidant defense system. Antioxidant enzymes play a major role in reducing ROS levels; 
therefore, redox regulation of transcription factors is significant in determining gene 
expression profile and cellular response to oxidative stress. There are different transcription 
factors involved in regulation of antioxidant enzymes and they can be regulated though 
IGFs signaling and others pathways related with receptors tyrosine kinases (RTKs). The 
most studied transcription factors are:  
Nrf2 transcription factor: Phosphorilated Nrf2 translocates to the nucleus and binds the ARE. 
ARE driven expression of detoxifying and antioxidant enzymes and the cystine/glutamate 
transporter involved in GSH biosynthesis [121,122].  
The PI3K/Akt/PP2A/GSK3ß and PKC/GSK3 play a role in regulation of Nrf2 and 
antioxidant gen regulation. PI3K pathway, consisting of p110 cataytic subunit and p85 
regulatory subunit, is tighly coupled with RTKs activated by various growth factors such 
as IGFs, Epidermal Growth Factor (EGF), Platelet-Derived Growth Factor (PDGF), Nerve 
Growth Factor (NGF), and Vascular Endothelial Growth Factor (VEGF). PI3K is recruited 
to activate RTK dimers through a SH2 domain in the PI3K p85 regulatory subunit. PI3K 
catalyzes the synthesis of the second messenger phosphatidylinositol 3,4,5 triphosphate 
(PIP3) from phosphatidylinositol 4,5 bisphosphate (PIP2), wherein the membrane bound 
PIP3 serves as a signaling molecule to recruit proteins containing the pleckstrin homology 
(PH) domain. These PH domain proteins, such as the phosphoinositide-dependent protein 
kinase (PDK) and protein kinase B (AKT) serine/threonine kinases are thus activated and 
mediate further downstream signaling events [123]. The synthesis of PIP3 is negatively 
regulated primarily by the phosphatase and tensin homology (PTEN) phosphatase, which 
dephosphorylates PIP3 back to PIP2 [124]. Through PTEN, the PI3K pathway is subject to 
reversible redox regulation by ROS generated by growth factor stimulation. H2O2 was 
shown to oxidize and inactivate human PTEN through disulfide bond formation between 
the catalytic domain Cys-124 and Cys-71 residues [125, 126]. It was also demonstrated that 
endogenously generated ROS following treatment with peptide growth factors such as 
IGFs, EGF, or PDGF causes oxidation of PTEN leading to the activation of the PI3K 
pathway [127]. PTEN oxidation is reversed by peroxiredoxin II, a cytoplasmic 
peroxiredoxin isoform that eliminates H2O2 generated in response to growth factors [125]. 
It is noteworthy that various oxidants and ROS-producing chemicals activate 
transcription of a battery of antioxidant genes through a PI3K-NFE2- like 2 (Nrf2)-
antioxidant response element (ARE) mechanism, where PTEN knockdown enhances 
transcription of ARE regulated antioxidant genes [128]. However, it is not known whether 
these oxidants induce PTEN oxidation and inhibition of phosphatase activity leading to 
gene activation. This leads to antioxidant gene expression that protects the cell. A role for 
NRF2 in drug resistance is suggested based on its property to induce detoxifying, drug 
transport, and antioxidant enzymes. 
 Antioxidant Enzyme 102 
FOXO transcription factors: FOXO-mediated upregulation of MnSOD expression results in 
considerable lowering of cellular ROS [129]. Increase in ROS enhances FOXO transcriptional 
activity, and thus functions as a feedback mechanism. An increase in ROS levels induces 
activation of the small GTPase Ral, which will in turn lead to the phosphorylation and 
activation of the stress kinase JNK. Active JNK induces the phosphorylation of on FOXO. 
Phosphorylation of these residues is essential for FOXO transcriptional activity as shown by 
mutational analysis. Consistent with this, H2O2 treatment increases FOXO transcriptional 
activity and translocation of FOXO from the cytoplasm to the nucleus and activation of the 
transcription factor. Activation of FOXO through can now induce transcription of MnSOD 
and CAT, leading to a decrease in ROS levels. Thus, activation of FOXO by oxidative stress 
is part of a negative feedback loop to reduce the levels of oxidative stress in a cell, 
preventing damage to DNA, lipids and proteins.  
Activation of PI3K/PKB signaling decreases FOXO activity and thus the levels of FOXO target 
genes like MnSOD and catalase [130]. Their regulation via PI-3K/PKB/FOXO signaling therefore 
implies that insulin, through this signaling cascade, may modulate the cellular ROS level. 
Based on oxidative stress is an imbalance between the production of ROS and antioxidative 
defenses systems, IGF-I decreases mitochondrial ROS production and IGF-I/Akt pathway is 
involved in Nrf2 and FOXO activity, both transcription factors involved in the antioxidative 
enzymes regulation. We propose that IGF-I can exert direct effects on cells and can alter in 
opposite ways the expression of antioxidant enzymes depending on the ROS levels. This 
regulation may contribute to the citoprotective effects of treatment with low doses of IGF-I in 
experimental “IGF-I deficiency” conditions [2, 5, 6, 40-42]. This model is summarized in Fig. 4. 
 
Figure 4. Regulation model of antioxidant enzymes mediated by IGF-I. IGF-I exerts a dual role depending on 
ROS concentration. High ROS levels increase antioxidant enzymes expression via Nfr2/ARE and low 
ROS levels decrease antioxidant enzymes expression via FOXO. 
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3. Aging and others conditions of “IGF-I deficiency” and oxidative stress 
Mechanisms that cellular protection against oxidative injure are not well understood. It 
is known, however, that factors that promote the generation of ROS and/or impair 
antioxidative processes contribute to oxidative damage. Oxidative damage accumulates 
with aging and is likely responsible for the progressive decline in physiological systems. 
The identification of physiological regulators of antioxidative processes is critical to the 
understanding of degenerative diseases and aging processes. GH, IGF-I, IGF-II 
concentrations decline with age. The IGF-I is an anabolic hormone produced mainly in 
the liver in response to GH stimulation [131]. Circulating IGF-I serum levels decline by 
more than 50% in healthy older adults [132, 133]. Our team results show that exogenous 
administration of low doses of IGF-I restores IGF-I circulating levels and some age-
related changes, improving glucose and lipid metabolisms, increasing testosterone levels 
and serum total antioxidant capability, and reducing oxidative damage in the brain and 
liver associated with a normalization of antioxidant enzyme activities and mitochondrial 
protection [5]. From these results we suggested that aging seems to be an unrecognized 
condition of “IGF-I deficiency.” The best-known condition of “IGF-I deficiency” is 
Laron’s dwarfism [134], characterized by an absence of GH receptors in the liver. 
Another condition of IGF-I deficiency is liver cirrhosis. In cirrhosis the reduction of 
receptors for GH in hepatocytes and the diminished ability of the hepatic parenchyma to 
synthesize cause a progressive decrease in serum IGF-I levels [135]. We have also shown 
previously that short courses of treatment with low doses of IGF-I in rats with carbon 
tetrachloride-induced cirrhosis had many systemic beneficial effects, and showed 
hepatoprotective and antioxidant properties, including mitochondrial protection [2, 3, 6, 
41]. 
Oxidative Stress is one of the most important mechanisms of the cellular damage in aging 
[42,131] and in others “IGF-I deficiency” conditions such as liver cirrhosis where there are a 
diminution in IGF-I levels but not in GH levels followed of a decrease in liver biosynthetic 
capacity. In order to reproduce of “IGF-I deficiency” condition and the possible benefices of 
treatment with low doses of IGF-I, we used two different experimental models: 
a. Experimental model of cirrhosis: Male Wistar rats in which liver cirrhosis was 
inducted using CCl4. IGF-I therapy or saline was administrated the last 4 weeks [2, 6, 
41, 137-139]. 
b. Experimental model of aging: Healthy male Wistar rats were divided into two groups 
according to age: young control of 17 weeks, and aging control rats of 103 weeks. Old 
animals were randomly assigned to receive either saline or human IGF-I [5, 
32,139,140].  
In these experimental groups we measured the oxidative stress by determination of: Total 
serum antioxidant status [40], liver contents of pro-oxidative metals [138] (iron and copper), 
parameters of oxidative damage such as lipid peroxidation (MDA), protein carboxyl content 
(PCC) and activities of antioxidant enzymes in homogenates of brain and liver.  
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Understanding that mitochondria are one of the most important cellular targets of IGF-I [5, 
6, 7] and they are the main intracellular ROS sources we studied the mitochondrial function by 
MMP, ATP synthesis, activities capase-3 processing and apoptosis in liver homogenates and 
isolated liver mitochondria [5, 41, 42] and intramitochondrial antioxidant capability of 
isolated liver mitochondria. 
In these conditions of “IGF-I deficiency” low doses of IGF-I induced: a increase in the total 
serum antioxidant capacity closely related with serum IGF-I levels [40], a correlation 
between the SODs levels and MDA as shown in Fig. 5, a decrease of oxidative cell damage 
reducing MDA and PCC and improving antioxidant enzyme activities and a mitochondrial 
protection improving MMP, proton leak and reducing intramitochondrial ROS production 
and increasing ATP synthesis (Fig. 6), leading to reduced apoptosis [5, 41, 42] . 
All these data together provide evidence of the beneficial effect of IGF-I replacement 
therapy inducing anabolic [139] and antioxidant [5, 40, 41,139] actions in both experimental 
“IGF-I deficiency” conditions: cirrhosis and aging and experimental basis for further studies 
at exploring the potential IGF-I like a bioprotector due to its antioxidant, hepatoprotective 
and neuoroprotective effects. Recently, we have also shown that IGF-II exerts similar effects 
[139,140]. The IGF-II is a peptide hormone that belongs to the family of IGFs. It plays an 
important role in the embryology development but the physiological function of IGF-II in 
the adult life are not fully understood [139,140]. IGF-II concentration decline with the age. 
Recently, we have also shown that low doses of IGF-II in aging rats exerts similar 








Figure 5. A) Correlation between TAS and IGF-I levels B) Correlation between SOD activity and MDA 
concentration  
 




Figure 6. Different mitochondrial parameters were measure by cytometry in isolated liver 
mitochondria from healthy young control animals, old rats and old rats treated with low doses of IGF-I: 
A) MMP is considered a good marker of mitochondrial function, B) ATP synthesis, C) Proton leak and 
D) ROS intramitochondrial production. 
4. Conclusions 
Our results show that the cytoprotective effect of IGFs is closely related to a mitochondrial 
protection, leading to the reduction of intramitocondrial free radical production, oxidative 
damage, and apoptosis, increased ATP production and a normalization of antioxidant 
enzyme activities. Further studies are necessary to elucidate all mechanisms involved in the 
IGFs mitochondrial protection, including the effects of IGF-I on autophagy of dysfunctional 
mitochondria and apoptosis. In agreement with these results, it has been reported that IGF-I 
differentially regulates Bcl-xL and Bax. Previously, we reported that low doses of IGF-I 
restored the expression of several protease inhibitors such us the serine protease inhibitor 2 
in cirrotic rats [137], which could contribute to the described mitochondrial protection. Our 
work provides new evidence of beneficial effect of IGF-I replacement therapy in 
degenerative diseases including aging. 
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Abbreviations 
Adenine Nucleotide Translocator (ANT) 
Amyotrophic Lateral Sclerosis (ALS) 
Antioxidants response elements (ARE) 
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Coenzyme Q10 (CoQ10) 
Copper and Zinc SOD (Cu-Zn SODs) 
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Glutathione (GSH) 
Glutathione Peroxidase (GSP) 
Glutathione Ttransferases (GST). 
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Growth factor hormone (GH), 
IGF-I receptor (IGF-1R) 
Inner mitochondrial membrane (IM), 
Insulin-like growth factor I (IGF-I) 
Manganese SOD (MnSOD) 
Mitochondrial DNA (mtDNA). 
Mitochondrial Membrane Permeability Transition (MMPT) 
Nerve Growth Factor (NGF) 
Nuclear Factor κ B (NFκB) 
Pentose phosphate pathway (PPP) 
Phosphatidylinositol 3, 4, 5 triphosphate (PIP3)  
Phosphatidylinositol 4, 5 bisphosphate (PIP2) 
Platelet-Derived Growth Factor (PDGF) 
Protein Carboxyl Content (PCC) 
Reactive Nitrogen Species (RNS) 
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Rhodamine 123 (Rh123) 
Superoxide Dismutase (SOD) 
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Thioredoxin (Trx) 
Tripenylphoshonium ion (TPP+) 
Tyrosine Kinases (RTKs) 
Vascular Endothelial Growth Factor (VEGF) 
Voltage-Dependent Anion Channel (VDAC) 
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